Skip to main content
. Author manuscript; available in PMC: 2013 May 23.
Published in final edited form as: Mol Cancer Ther. 2009 Aug 11;8(8):2356–2365. doi: 10.1158/1535-7163.MCT-08-1183

Figure 1. MC4R and δOR saturation binding and competitive binding analysis.

Figure 1

A. Saturation binding of Eu-DPLCE ligand to δOR in CHO/MC4R/δOR cells. The curve shows δOR specific binding only (total-nonspecific). From these data, the Kd = 10.5 ± 2.6 nM and Bmax = 24,000 ± 2,000 AFU (R2 = 0.91). Each data point indicates the average of four samples, with error bars indicating the standard error of the mean. B. Saturation binding assay of Eu-NDP-α-MSH ligand to MC4R in CHO/MC4R/δOR cells. The curve shows MC4R specific binding only. From these data, the Kd = 5.6 ± 2.7 nM and Bmax = 7,700 ± 1,400 AFU (R2 = 0.83). C-D. Competitive binding to CHO cells co-expressing MC4R and δOR. C. Increasing concentrations of Naloxone were added in the presence of 10 nM Eu-DPLCE. From these data, the IC50 was 65 nM with R2 = 0.90. D. Increasing concentration of NDP-α-MSH were added to cells in the presence of 10 nM Eu- NDP-α-MSH. From these data, IC50 was 0.77 nM with R2 = 0.89.